{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:45:37Z","timestamp":1793929537326,"version":"4.8.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.eururo.2023.12.014","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T13:34:06Z","timestamp":1704461646000},"page":"417-421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3873-7465","authenticated-orcid":false,"given":"Filippo","family":"Pederzoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Riba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Venegoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Marandino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Alchera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Raggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Giannatempo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Provero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejan","family":"Lazarevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Lucian\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gallina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Salonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6904-9158","authenticated-orcid":false,"given":"Massimo","family":"Alfano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2023.12.014_b0005","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3322\/caac.21631","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2023.12.014_b0010","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.annonc.2020.09.011","article-title":"Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study","volume":"31","author":"Bandini","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2023.12.014_b0015","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2023.12.014_b0020","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.eururo.2021.05.018","article-title":"Is there a detrimental effect of antibiotic therapy in patients with muscle-invasive bladder cancer treated with neoadjuvant pembrolizumab?","volume":"80","author":"Pederzoli","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.12.014_b0025","series-title":"Neoadjuvant immunotherapy treatment of localized genitourinary cancers: multidisciplinary management","first-page":"247","article-title":"The gut and urinary microbiota: a rising biomarker in genitourinary malignancies","author":"Pederzoli","year":"2022"},{"key":"10.1016\/j.eururo.2023.12.014_b0030","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.eururo.2023.12.014_b0035","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.eururo.2023.12.014_b0040","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-22-2158","article-title":"Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial","volume":"28","author":"Basile","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2023.12.014_b0045","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature14139","article-title":"Vertically transmitted faecal IgA levels determine extra-chromosomal phenotypic variation","volume":"521","author":"Moon","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2023.12.014_b0050","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.3389\/fmicb.2016.01706","article-title":"Mucosal prevalence and interactions with the epithelium indicate commensalism of Sutterella spp","volume":"7","author":"Hiippala","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.eururo.2023.12.014_b0055","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jtho.2019.04.007","article-title":"The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC","volume":"14","author":"Jin","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.eururo.2023.12.014_b0060","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.eururo.2023.12.014_b0065","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.eururo.2023.12.014_b0070","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.euo.2020.04.002","article-title":"Sex-specific alterations in the urinary and tissue microbiome in therapy-na\u00efve urothelial bladder cancer patients","volume":"3","author":"Pederzoli","year":"2020","journal-title":"Eur Urol Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283823033419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283823033419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T20:29:05Z","timestamp":1729110545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283823033419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0302283823033419"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2023.12.014","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2023.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}